Antibiotic prophylaxis reduced symptomatic urinary tract infection in children with vesicoureteral reflux, but not scarring

Author(s):  
Philipp Dahm ◽  
Jane M. Lewis

This chapter summarizes the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial, a landmark trial that randomized children with vesicoureteral reflux diagnosed after a first or second febrile or symptomatic urinary tract infection to receive trimethoprim–sulfamethoxazole (TMP-SMX) prophylaxis versus placebo. It found that antibiotic prophylaxis reduced the incidence of recurrent febrile or symptomatic urinary tract infection but had little effect on renal scarring. Recurrent febrile or symptomatic urinary tract infections resistant pathogens were increased. This study provides the underpinning for guidelines that advocate for low-dose antibiotic prophylaxis for the first year of life; however, this remains an area of considerable controversy.


2018 ◽  
Vol 38 (3) ◽  
pp. 196-199
Author(s):  
Kazuto Taniguchi ◽  
Sakumo Kii ◽  
Masafumi Oka ◽  
Kazuyasu Uemichi

Vesicoureteral reflux is a common condition in infants with urinary tract infection. Although antibiotic prophylaxis to prevent recurrent urinary tract infection is widely performed, its effectiveness remains controversial. Herein we report a seven- month-old boy with vesicoureteral reflux. Antibiotic prophylaxis with amoxicillin caused microbial resistance accompanied by recurrent urinary tract infection. Subsequent antibiotic prophylaxis with sulfamethoxazole-trimethoprim was effective until spontaneous remission of vesicoureteral reflux occurred. Sulfamethoxazole-trimethoprim, but not amoxicillin, should be considered as an agent for antibiotic prophylaxis in infants with vesicoureteral reflux.


Sign in / Sign up

Export Citation Format

Share Document